Editorial
|
|
|
BigPharma should mind its own business
|
|
|
New Products
|
|
|
More potential problems than benefits
|
|
|
|
|
|
|
|
|
Another 'atypical neuroleptic'; QT prolongation
|
|
|
|
|
|
|
More risks than in adults
|
|
|
|
|
|
A welcome low-dose formulation for neonates
|
|
|
|
|
|
Adverse effects outweigh the benefits
|
|
|
|
|
|
|
A combination with no proven advantages
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
A useful concept for drug companies, useless for patients
|
|
|
|
|
|
|
|
|
|
|
|
|